Lead Bank & BIO Helix Sponsor


Host Bank & BIO Helix Sponsor


Supporting Bank Sponsor



BIO Double Helix Sponsors




BIO Helix Sponsors






Conference Sponsors














Infectious Disease: Reinforcements on the Way - A Surge of New Treatments to Combat HCV

Monday, February 9th
1:45 - 2:55 pm
East Foyer

The paradigm for the treatment of Hepatitis C is changing rapidly with the introduction of Direct-Acting Anti-Viral (DAAV) therapies.  Leading the way are the protease inhibitors which may offer shorter treatment durations with improved cure rates as measured by sustainable viral load reduction.  Not far behind are other classes of DAAV therapies such as the nucleosides and non-nucleosides.  In 2009 the market will get its first look at phase III efficacy from an oral combination of DAAV therapy.  This panel will explore the changing HCV landscape, role of new diagnostics, and factors driving the market.  Our experts will also compare and contrast HCV and HIV treatment patterns and discuss the implications on product life cycles and the future of HCV combination therapy. 

Moderator

Panelists

Who's Who

Douglas T. Dieterich, MD; Dr. Dieterich is a Professor of Medicine, Director of Outpatient Hepatology in the Division of Liver Diseases, and Director of CME in the Department of Medicine at Mount Sinai School of Medicine in New York, NY.  He has triple appointments in the Divisions of Liver Disease, Gastroenterology, and Infectious Diseases.  He is an investigator for many ongoing studies evaluating the safety and efficacy of new small molecule antiviral treatments for chronic Hepatitis B and C.  Dr. Dierterich recieved his medical degree from New York University School of Medicine and completed his internship and residency in internal medicine from Bellevue Hospital Center in New York, where he was also a fellow in the Div. of Gastroenterology.  He has served on several committees of the AIDS Clinical Trials Group and NIH.  He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and Protozoan Committee.  Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts, and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal system.

Barry Labinger; Mr. Labinger joined HGS in August 2005 as Executive Vice President and Chief Commercial Officer. Mr. Labinger has more than 15 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Mr. Labinger was most recently with 3M Pharmaceuticals, where he served as Division Vice President. 3M Pharmaceuticals is a global division of 3M Company with marketed products in dermatology, women’s health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University.

Stephen Chris Pappas, MD; Dr. Pappas is the Director of Clinical Research at the St. Luke’s Texas Liver Institute in Houston, Texas. He is a clinical and regulatory consultant in the healthcare and pharmaceutical industry with expertise in both the clinical and research perspective of viral hepatitis. In addition, Dr. Pappas has experience in the commercialization of therapies for hepatitis C and was part of the core group responsible for the successful launch of a billion dollar product in this therapeutic area.

Stephen T. Worland, Ph.D; Dr. Worland was appointed President and Chief Executive Officer and a member of the Board of Directors in 2007. Dr. Worland joined Anadys in 2001 as Chief Scientific Officer and served as President, Pharmaceuticals prior to being named CEO. Prior to joining Anadys, Dr. Worland was Vice President, Head of Antiviral Research at Agouron Pharmaceuticals, a Pfizer Company. Dr. Worland was at Agouron from 1988 through the acquisition of Agouron by Warner-Lambert in 1999, where he held various positions and responsibilities that culminated with him assuming global responsibility for anti-infective strategy as Vice President for Warner-Lambert. At Agouron, Warner-Lambert and Pfizer, Dr. Worland led teams responsible for discovery and clinical development in the areas of HIV, HCV and respiratory infections. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.